Pompe's disease
- PMID: 18929906
- DOI: 10.1016/S0140-6736(08)61555-X
Pompe's disease
Abstract
Pompe's disease, glycogen-storage disease type II, and acid maltase deficiency are alternative names for the same metabolic disorder. It is a pan-ethnic autosomal recessive trait characterised by acid alpha-glucosidase deficiency leading to lysosomal glycogen storage. Pompe's disease is also regarded as a muscular disorder, but the generalised storage of glycogen causes more than mobility and respiratory problems. The clinical spectrum is continuous and broad. First symptoms can present in infants, children, and adults. Cardiac hypertrophy is a key feature of classic infantile Pompe's disease. For a long time, there was no means to stop disease progression, but the approval of enzyme replacement therapy has substantially changed the prospects for patients. With this new development, the disease is now among the small but increasing number of lysosomal storage disorders, for which treatment has become a reality. This review is meant to raise general awareness, to present and discuss the latest insights in disease pathophysiology, and to draw attention to new developments about diagnosis and care. We also discuss the developments that led to the approval of enzyme replacement therapy with recombinant human alpha-glucosidase from Chinese hamster ovary cells (alglucosidase alfa) by the US Food and Drug Administration and European Medicines Agency in 2006, and review clinical practice.
Similar articles
-
Late-onset Pompe's disease.Semin Neurol. 2012 Nov;32(5):506-11. doi: 10.1055/s-0033-1334469. Epub 2013 May 15. Semin Neurol. 2012. PMID: 23677658 Review.
-
Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy.Muscle Nerve. 2003 Jun;27(6):743-51. doi: 10.1002/mus.10381. Muscle Nerve. 2003. PMID: 12766987
-
[Enzyme replacement therapy in Pompe's disease].Med Klin (Munich). 2007 Jul 15;102(7):570-3. doi: 10.1007/s00063-007-1070-z. Med Klin (Munich). 2007. PMID: 17634875 German.
-
Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up.Ann Neurol. 2004 Apr;55(4):495-502. doi: 10.1002/ana.20019. Ann Neurol. 2004. PMID: 15048888
-
The natural course of non-classic Pompe's disease; a review of 225 published cases.J Neurol. 2005 Aug;252(8):875-84. doi: 10.1007/s00415-005-0922-9. J Neurol. 2005. PMID: 16133732 Review.
Cited by
-
Golgi defect as a major contributor to lysosomal dysfunction.Front Cell Dev Biol. 2024 Apr 24;12:1386149. doi: 10.3389/fcell.2024.1386149. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 38721528 Free PMC article. Review.
-
Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy.Front Immunol. 2024 Apr 23;15:1336599. doi: 10.3389/fimmu.2024.1336599. eCollection 2024. Front Immunol. 2024. PMID: 38715621 Free PMC article. Clinical Trial.
-
Real-world evidence study finds no new-onset diabetes or drug-related hyperglycemia in Pompe disease patients treated with avalglucosidase alfa.Mol Genet Metab Rep. 2024 Feb 20;38:101064. doi: 10.1016/j.ymgmr.2024.101064. eCollection 2024 Mar. Mol Genet Metab Rep. 2024. PMID: 38469102 Free PMC article.
-
104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07).J Neurol. 2024 May;271(5):2810-2823. doi: 10.1007/s00415-024-12236-0. Epub 2024 Feb 28. J Neurol. 2024. PMID: 38418563 Free PMC article. Clinical Trial.
-
The Importance of Early Treatment of Inherited Neuromuscular Conditions.J Neuromuscul Dis. 2024;11(2):253-274. doi: 10.3233/JND-230189. J Neuromuscul Dis. 2024. PMID: 38306060 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical